Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $963.65M |
| Gross Profit (TTM) | $949.55M |
| EBITDA | $113.14M |
| Operating Margin | 33.70% |
| Return on Equity | 22.20% |
| Return on Assets | 7.46% |
| Revenue/Share (TTM) | $9.17 |
| Book Value | $7.62 |
| Price-to-Book | 9.29 |
| Price-to-Sales (TTM) | 8.26 |
| EV/Revenue | 7.66 |
| EV/EBITDA | 64.85 |
| Quarterly Earnings Growth (YoY) | 531.00% |
| Quarterly Revenue Growth (YoY) | 64.00% |
| Shares Outstanding | $109.44M |
| Float | $97.69M |
| % Insiders | 11.32% |
| % Institutions | 75.32% |
Volatility is currently contracting
Corcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published their consensus report on the Management of Type 2 Diabetes, 2026.
CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
ROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
As inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CORT and any ticker you trade — then tracks every position and per-strategy win rate.
